Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer

L. Livi; I. Meattini; C. de Luca Cardillo; V. Scotti; B. Agresti; C. Franzese; L. Sanchez; J. Nori; S. Bertocci; S. Cassani; S. Bianchi; L. Cataliotti; G. Biti

Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer

L. Livi, I. Meattini, C. de Luca Cardillo, V. Scotti, B. Agresti, C. Franzese, L. Sanchez, J. Nori, S. Bertocci, S. Cassani, S. Bianchi, L. Cataliotti, G. Biti

Istituto Clinico Humanitas

Research output: Contribution to journal › Article › peer-review

Abstract

We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our Institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (Pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.

Original language	English
Pages (from-to)	36-39
Number of pages	4
Journal	Journal of Chemotherapy
Volume	23
Issue number	1
Publication status	Published - Feb 2011

Keywords

Adjuvant chemotherapy
Anthracycline
Breast cancer
Cardiac safety
Docetaxelreferences

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Oncology
Pharmacology
Medicine(all)

Access to Document

Fingerprint Dive into the research topics of 'Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer'. Together they form a unique fingerprint.

Cite this

Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer. / Livi, L.; Meattini, I.; de Luca Cardillo, C.; Scotti, V.; Agresti, B.; Franzese, C.; Sanchez, L.; Nori, J.; Bertocci, S.; Cassani, S.; Bianchi, S.; Cataliotti, L.; Biti, G.

In: Journal of Chemotherapy, Vol. 23, No. 1, 02.2011, p. 36-39.

Research output: Contribution to journal › Article › peer-review

@article{0677939206ce4467a02dcaef5105354f,

title = "Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer",

abstract = "We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our Institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (Pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.",

keywords = "Adjuvant chemotherapy, Anthracycline, Breast cancer, Cardiac safety, Docetaxelreferences",

author = "L. Livi and I. Meattini and {de Luca Cardillo}, C. and V. Scotti and B. Agresti and C. Franzese and L. Sanchez and J. Nori and S. Bertocci and S. Cassani and S. Bianchi and L. Cataliotti and G. Biti",

year = "2011",

month = feb,

language = "English",

volume = "23",

pages = "36--39",

journal = "Journal of Chemotherapy",

issn = "1120-009X",

publisher = "Maney Publishing",

number = "1",

}

TY - JOUR

T1 - Use of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant chemotherapy for beast cancer

AU - Livi, L.

AU - Meattini, I.

AU - de Luca Cardillo, C.

AU - Scotti, V.

AU - Agresti, B.

AU - Franzese, C.

AU - Sanchez, L.

AU - Nori, J.

AU - Bertocci, S.

AU - Cassani, S.

AU - Bianchi, S.

AU - Cataliotti, L.

AU - Biti, G.

PY - 2011/2

Y1 - 2011/2

N2 - We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our Institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (Pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.

AB - We evaluated the feasibility and incidence of hematological toxicity in a series of 39 breast cancer patients treated at our Institute with doxorubicin plus cyclophosphamide (AC) followed by docetaxel, using prophylactic G-CSF (Pegfilgrastim). We prescribed G-CSF as secondary prophylaxis during the AC regimen and as primary prophylaxis during treatment with docetaxel. For the AC treatment, we recorded 6 cases of grade III (15.3%) and one case of grade IV (2.5%) neutropenia; we found one case of Grade IV anemia. For the docetaxel regimen, we registered one case of Grade IV (2.5%) neutropenia and three cases of Grade III leukopoenia without neutropenia. No patients experienced cardiac symptoms or baseline LVEF rate decrease. All patients concluded the programmed chemotherapy. Our experience shows the safety of docetaxel in combination with anthracyclines and the efficacy of prophylaxis with G-CSF in breast cancer adjuvant chemotherapy.

KW - Adjuvant chemotherapy

KW - Anthracycline

KW - Breast cancer

KW - Cardiac safety

KW - Docetaxelreferences

UR - http://www.scopus.com/inward/record.url?scp=80051713381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051713381&partnerID=8YFLogxK

M3 - Article

C2 - 21482493

AN - SCOPUS:80051713381

VL - 23

SP - 36

EP - 39

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 1

ER -